Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treat the Cancer, But Take Care to Protect the Heart

30.06.2004


Cancer treatments, including the most commonly used chemotherapy agents as well as the newest biologic and targeted therapy drugs, can harm a patient’s heart, sometimes fatally – but many physicians do not adequately monitor their patients for such damage or manage their care to minimize it.



So say cardiologists at The University of Texas M. D. Anderson Cancer Center, who published, in the June 29 issue of the journal Circulation, the first large scale review detailing cardiovascular complications that often occur in cancer therapy, as well as ways to prevent or treat them.

The study draws on 30 years of experience at M. D. Anderson Cancer Center as well as on the current body of research on the cardiotoxicity of various agents.


The findings are important because both patients and doctors may not be aware of the spectrum of heart problems that can arise from cancer treatment, or know that many of these problems can be managed, says the study’s lead author, Edward T. H. Yeh, M.D., professor and chairman of the Department of Cardiology.

“Many cancer survivors will actually be at greater risk from cardiac disease as from recurrent cancer,” says Yeh. “Now that cancer is often being treated as a chronic, manageable disease, it is critical that this treatment doesn’t substantially weaken a patient’s heart.”

In fact, Yeh and a team of nine other cardiologists from M. D. Anderson found in their review of 29 anticancer agents that there is no class of cancer drug that is free of potential damage to the heart, the organ that seems to be most sensitive to toxic effects of anticancer agents.

Generally speaking, patients at most risk for cardiotoxicity are those who are aged and have other illnesses, such as diabetes or existing heart disease, he says. But cardiotoxicity can occur in any patient, either during treatment or months, even years after treatment.

Even the newest targeted therapies, designed to attack only cancer cells, can cause cardiotoxicity, Yeh says. For example, monoclonal antibody drugs such as Avastin, Erbitux, and Rituxin produce a significant amount of hypertension as well as hypotension in patients. “They seem to have more general toxicity than many other agents, but the problems they produce usually involve changes in blood pressure, which can be easily treated if recognized,” Yeh says.

Some agents, however, are clearly more dangerous, especially in large doses. For example, patients using the common class of chemotherapy drugs known as anthracyclines/anthraquinolones that includes adriamycin should be closely monitored because these agents frequently produce irreversible chronic heart failure or left ventricular dysfunction, says Yeh. “This is probably the most problematic class of anticancer drugs, but with experience, cardiotoxicity can be limited,” he says.

Alkylating agents, another class of common chemotherapy drugs, have other toxic effects. Platinol and Cytoxan, the most widely used alkylating agents, can produce heart problems that range from chronic heart failure to hypertension, if the total dose is high.

Chemotherapy drugs known as “antimetabolites,” which include the widely used agent 5-fluorouracil (5-FU), can produce ischemia, which can lead to heart attacks if not treated. However, heart problems are relatively rare in the “antimicrotubules” class of chemotherapy drugs, of which Taxol is a member.

Other non-chemotherapy drugs noted for their high risk of cardiotoxicity includes Inerleukin-2, which frequently results in hypotension or arrhythmias; Gleevec which can cause heart failure; Trisenox, from which fatal “QT prolongation” can result; and Thalidomide, which can produce a variety of serious heart ailments.

On the other hand, the researchers found that Herceptin is less toxic than generally believed, although it can cause chronic heart failure and left ventricular dysfunction.

“We found a profile of cardiotoxicity for the most often used anticancer drugs, but it is important to know that every patient has different risk factors that will determine how their hearts handle the treatment,” says Yeh. “Monitoring and management is key to surviving cancer with a good and lasting heart.”

The study was funded by the Department of Cardiology at MD Anderson Cancer Center. Co-authors include Michael Ewer, M.D., Ann Tong, M.D., Daniel Lenihan, M.D., S. Wamique Yusuf, M.D., Joseph Swafford, M.D., Christopher Champion, M.D., Jean-Bernard Durand, M.D., Harry Gibbs, M.D., and Alireza Zafarmand, M.D.

| newswise
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Mutations in donors' stem cells may cause problems for cancer patients
17.01.2020 | Washington University School of Medicine

nachricht Overactive brain waves trigger essential tremor
17.01.2020 | Columbia University Irving Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Miniature double glazing: Material developed which is heat-insulating and heat-conducting at the same time

Styrofoam or copper - both materials have very different properties with regard to their ability to conduct heat. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz and the University of Bayreuth have now jointly developed and characterized a novel, extremely thin and transparent material that has different thermal conduction properties depending on the direction. While it can conduct heat extremely well in one direction, it shows good thermal insulation in the other direction.

Thermal insulation and thermal conduction play a crucial role in our everyday lives - from computer processors, where it is important to dissipate heat as...

Im Focus: Fraunhofer IAF establishes an application laboratory for quantum sensors

In order to advance the transfer of research developments from the field of quantum sensor technology into industrial applications, an application laboratory is being established at Fraunhofer IAF. This will enable interested companies and especially regional SMEs and start-ups to evaluate the innovation potential of quantum sensors for their specific requirements. Both the state of Baden-Württemberg and the Fraunhofer-Gesellschaft are supporting the four-year project with one million euros each.

The application laboratory is being set up as part of the Fraunhofer lighthouse project »QMag«, short for quantum magnetometry. In this project, researchers...

Im Focus: How Cells Assemble Their Skeleton

Researchers study the formation of microtubules

Microtubules, filamentous structures within the cell, are required for many important processes, including cell division and intracellular transport. A...

Im Focus: World Premiere in Zurich: Machine keeps human livers alive for one week outside of the body

Researchers from the University Hospital Zurich, ETH Zurich, Wyss Zurich and the University of Zurich have developed a machine that repairs injured human livers and keep them alive outside the body for one week. This breakthrough may increase the number of available organs for transplantation saving many lives of patients with severe liver diseases or cancer.

Until now, livers could be stored safely outside the body for only a few hours. With the novel perfusion technology, livers - and even injured livers - can now...

Im Focus: SuperTIGER on its second prowl -- 130,000 feet above Antarctica

A balloon-borne scientific instrument designed to study the origin of cosmic rays is taking its second turn high above the continent of Antarctica three and a half weeks after its launch.

SuperTIGER (Super Trans-Iron Galactic Element Recorder) is designed to measure the rare, heavy elements in cosmic rays that hold clues about their origins...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

 
Latest News

A new 'cool' blue

17.01.2020 | Life Sciences

EU-project SONAR: Better batteries for electricity from renewable energy sources

17.01.2020 | Power and Electrical Engineering

Neuromuscular organoid: It’s contracting!

17.01.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>